SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales declined to Rs. 104.79 millions for the June 2022 quarter as compared to Rs. 142.15 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2022 is Rs. -49.96 millions as compared to Net Profit of Rs. 19.27 millions of corresponding quarter ended June 2021Operating profit Margin for the quarter ended June 2022 slipped to -46.86% as compared to 12.89% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 104.79 142.15 -26.28 104.79 142.15 -26.28 783.88 853.34 -8.14
Other Income 1.44 2.49 -42.17 1.44 2.49 -42.17 11.02 16.79 -34.37
PBIDT -46.86 12.89 -463.54 -46.86 12.89 -463.54 -38.84 -191.93 -79.76
Interest 15.80 11.56 36.68 15.80 11.56 36.68 55.92 47.77 17.06
PBDT -62.66 1.33 -4811.28 -62.66 1.33 -4811.28 -94.76 -239.70 -60.47
Depreciation 0.37 0.59 -37.29 0.37 0.59 -37.29 2.13 2.37 -10.13
PBT -63.03 0.74 -8617.57 -63.03 0.74 -8617.57 -96.89 -242.07 -59.97
TAX -13.07 -18.53 -29.47 -13.07 -18.53 -29.47 -9.34 -60.95 -84.68
Deferred Tax -13.07 -18.53 -29.47 -13.07 -18.53 -29.47 -9.34 -60.95 -84.68
PAT -49.96 19.27 -359.26 -49.96 19.27 -359.26 -87.55 -181.12 -51.66
Equity 431.80 431.80 0.00 431.80 431.80 0.00 431.80 431.80 0.00
PBIDTM(%) -44.72 9.07 -593.15 -44.72 9.07 -593.15 -4.95 -22.49 -77.97

Bharat Immunological Share Price

17.20 0.34 (2.02%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×